Search - tctmd.com

Displaying 61 - 80 of 267

Sort: Relevancy | Date

Presentation NY Valves 2024

Will New VHD Screening Methods Address or Exacerbate Healthcare Disparities?

Presenter: Suzanne J. Baron

June 06, 2024

Presentation NY Valves 2024

Asymmetric Expansion of Balloon Expandable Transcatheter Aortic Valve Prostheses: Implications for Valve Hemodynamics and Clinical Outcomes

Presenter: Annette Maznyczka

June 06, 2024

Presentation NY Valves 2024

Determinants of Intervention Type and All-Cause Mortality of TAVR and SAVR Patients Younger Than 75 Years in the Netherlands

Presenter: Nicolas M. Van Mieghem

June 06, 2024

Presentation NY Valves 2024

Designing Trials to Assess the Effectiveness of New VHD Screening Strategies

Presenter: Timothy Joseph Poterucha

June 06, 2024

Presentation NY Valves 2024

Gradients After Transcatheter Aortic Valve Replacements Are Impacted by Both Body Mass Index and Valve Size

Presenter: Akhil Reddy

June 06, 2024

Presentation NY Valves 2024

Echo-Derived Gradients Increase at 30 Days in Most Patients After Balloon-Expandable TAVR Irrespective of Valve Type and Valve Size

Presenter: Spencer Ng

June 06, 2024

Presentation NY Valves 2024

Screening for VHD: Beyond Proof of Concept to Implementation and Scaling

Presenter: Sammy Elmariah

June 06, 2024

Presentation NY Valves 2024

Female Sex Is Not Associated With Increased Vascular Afterload in Older Patients With Aortic Stenosis

Presenter: Sara Hungerford

June 06, 2024

Presentation NY Valves 2024

The Landscape of Novel Methods to Screen for VHD

Presenter: Sreekanth Vemulapalli

June 06, 2024

Presentation NY Valves 2024

Invasive Versus Echocardiographic Transvalvular Pressure Gradients After Transcatheter Aortic Valve Implantation

Presenter: Eishan Ashwat

June 06, 2024

Presentation NY Valves 2024

Invasive Exercise Hemodynamics in Aortic Stenosis

Presenter: Abdullah Al-Abcha

June 06, 2024

Presentation NY Valves 2024

The Importance of Patient Reported Outcomes in VHD

Presenter: Suzanne V. Arnold

June 06, 2024

Presentation NY Valves 2024

Diversity and Under Represented Populations in VHD: Focusing on Real Solutions

Presenter: Annetine C. Gelijns, Megan Coylewright

June 06, 2024

Presentation NY Valves 2024

Using Real-world Data in VHD: Sources, Successes, and Failures

Presenter: Sreekanth Vemulapalli

June 06, 2024

Presentation NY Valves 2024

Long-term Follow-up in VHD Clinical Trials: Much Needed, BUT Difficult to Do

Presenter: Mauro Moscucci

June 06, 2024

Presentation NY Valves 2024

Challenges With Vulnerable, Underrepresented Populations

Presenter: Clyde W. Yancy

June 06, 2024

Presentation NY Valves 2024

Trialist Perspective

Presenter: Roxana Mehran

June 06, 2024

Presentation NY Valves 2024

Industry Perspective

Presenter: Janarthanan Sathananthan

June 06, 2024

Presentation NY Valves 2024

FDA Perspective

Presenter: Lisa Plummer

June 06, 2024

Presentation NY Valves 2024

Secondary MR and GDMT Titration Before M-TEER in the Real-world

Presenter: Donna Mancini

June 05, 2024

Advertisement

Will New VHD Screening Methods Address or Exacerbate Healthcare Disparities?

Asymmetric Expansion of Balloon Expandable Transcatheter Aortic Valve Prostheses: Implications for Valve Hemodynamics and Clinical Outcomes

Determinants of Intervention Type and All-Cause Mortality of TAVR and SAVR Patients Younger Than 75 Years in the Netherlands

Designing Trials to Assess the Effectiveness of New VHD Screening Strategies

Gradients After Transcatheter Aortic Valve Replacements Are Impacted by Both Body Mass Index and Valve Size

Echo-Derived Gradients Increase at 30 Days in Most Patients After Balloon-Expandable TAVR Irrespective of Valve Type and Valve Size

Screening for VHD: Beyond Proof of Concept to Implementation and Scaling

Female Sex Is Not Associated With Increased Vascular Afterload in Older Patients With Aortic Stenosis

The Landscape of Novel Methods to Screen for VHD

Invasive Versus Echocardiographic Transvalvular Pressure Gradients After Transcatheter Aortic Valve Implantation

Invasive Exercise Hemodynamics in Aortic Stenosis

The Importance of Patient Reported Outcomes in VHD

Diversity and Under Represented Populations in VHD: Focusing on Real Solutions

Using Real-world Data in VHD: Sources, Successes, and Failures

Long-term Follow-up in VHD Clinical Trials: Much Needed, BUT Difficult to Do

Challenges With Vulnerable, Underrepresented Populations

Trialist Perspective

Industry Perspective

FDA Perspective

Secondary MR and GDMT Titration Before M-TEER in the Real-world

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content